Transcription
Biomemed Nexus Daily updates your essential biotech, medtec, and pharma recap. No noise, just what matters. TLDDR.
GTC 2026 kicks off. Ro claims pharma's largest GPU footprint. 3,500 plus Blackwell chips. Lily showcases Lily Pod. Jensen Huang keynote sets AI in pharma rhythm. PDUFA. Friday, IMIV decision for acquired hypothalamic obesity lands. March 20th.
ACP meets Wednesday, Thursday. Kennedy era committee to debate COVID vaccine injuries. WOST and 30 states have already decoupled from CDC guidance. Liner PDUFA next week. Alpha Sigma controlled asset gets FDA verdict March 24th. Executive takeaway.
The pharma GPU arms race went vertical yesterday. Rosh announced 20 among 76 new Blackwell GPUs, bringing its total to 3,500 plus, claiming the industry's largest compute footprint. Lily counted that its Lily Pod 1016 Blackwell Ultra chips is the most powerful wholly-owned AI factory in BioPharma. Different benchmarks, same message. Wet lab throughput is no longer the bottleneck. Dry lab simulation is the companies running the biggest models fastest will compress discovery timelines, or at least that's the bet. Al's warning at Lily's launch is worth remembering. The hype is actually a serious threat to the research itself.
Read full analysis.
What to watch.
Date: March 18-19. Event: ACIP meeting, virtual. First Kennedy era meeting with COVID vaccine injury agenda. AAP lawsuit pending.
March 20. Rhythm. IMI. Acquired hypothalamic obesity SNDA. Phase 3 showed 16.5% BMI reduction.
March 24. GSK, Alpha Sigma. Linerat PDUFA. Pruritus in PBC. Gliston phase 3 hit endpoints.
March 26. Novo Nordisk AGM. Board elections amid 34% holdings asset decline. GLP1 defense under scrutiny.
March 28. Rocket Pharma. Chrysladi PDUFA. Gene therapy 100% OS at 12 months. PRV eligible.
Today's Top Story.
Pharma's GPU arms race escalates at GTC 2026. Nvidia's annual GPU Technology Conference opened in San Jose yesterday with a pharma subplot. Ro and Lily are now locked in a compute capacity measuring contest.
Ro March 16th deployed 2,176 new Nvidia Blackwell GPUs across US and European sites. Combined on-premise plus cloud footprint now exceeds 3,500 GPUs. Claims greatest announced GPU footprint available to a pharmaceutical company using Biono platform for biological foundation models. Omniverse for manufacturing digital twins. One application already live: digital twin of Ro's new GLP1 manufacturing facility in North Carolina.
Lily announced Feb 26, showcased at GTC. Lily Pod uses 1016 Blackwell Ultra GPUs in a DGX Super Pod, claims most powerful AI factory wholly owned and operated by a pharmaceutical company. 9,000+ petaflops of AI performance built in 4 months in Indianapolis. Dry lab can simulate billions of molecular hypotheses simultaneously versus 2,000 molecules each year in traditional wet labs.
The gap with hyperscalers remains vast. XAI's Colossus cluster runs 500,000+ GPUs. Meta's Louisiana facility is targeting millions, but within pharma, the GPU buildout is accelerating. Ro, Lily, and Recursion now collectively deploy 5,000+ chips.
What matters for investors: Neither company has tied a specific clinical candidate to its AI infrastructure yet. The first credible AI-discovered, AI-accelerated approval will be the proof point. Until then, these are expensive positioning bets.
AI and Digital Health.
Jensen Huang keynote highlights March 16th. Framed the token as the basic unit of modern AI, from scientific discovery to robotics. Nvidia Vera CPU launched, purpose-built for agentic AI and reinforcement learning. Nvidia Vera Rubin platform. Seven new chips in full production for AI factory scale-up.
Kimberly Powell, Nvidia VP, Healthcare Life Sciences session. Nearly 90% of eligible small molecule programs at Genentech now integrate AI. Oncology molecule designed 25% faster. Backup candidate delivered in 7 months. Expects AI-assisted discovery benefits to materialize around 2030.
Corporate Developments.
Trump Rx expansion. GSK and Amgen formally added to TrumpRx.gov last week, bringing total to 54 medications from six manufacturers. Amgen offering Amjivvita at 80% off retail ($299,484). Imavig and Repatha at 62% discounts. GSK listing in Cruz 55% off. Anuity, Relenza, and Anoro 10-51% off. Total Trump RX participants now include FISA, AstraZeneca, Eli Lilly, Novo Nordisk, EMD Serono, GSK, Amgen, China.
BCI milestone March on the 13th. NMPA approved Neural Technologies implantable brain computer interface. First commercial BCI approval globally, indicated for adults 18-60 with cervical spinal cord injury quadriplegia. Coin-size device on brain surface controls pneumatic glove for grasping. 36-patient trial 100% achieved home-based brain control grasp, no device-related SAEs reported. Chinese BCI funding surge: Stair raised $72.8M. Aid Meditors, Alibaba, Le Gustala raised £21.6M.
Week Ahead.
Key Catalysts.
Wednesday-Thursday. ACIP Meeting. The CDC's Advisory Committee on Immunization Practices meets virtually March 18th to 19th. Agenda includes COVID-19 vaccine injuries and Long COVID discussions. ACIP recommendation methodology changes, potential votes on all three items.
Context: This is the first meeting since RFK Jr. replaced all committee members last summer. The American Academy of Obstetricians and Gynecologists withdrew as a liaison member, citing concerns about cherry-picking of data. An AAP lawsuit sought to stop the meeting, and 30 states have already decoupled from CDC vaccine guidance.
Friday. Rhythm. IMI. PDUFA, March 20th. Indication: Acquired Hypothalamic Obesity (AHO) SNDA. Phase three TRANSCEND results: 16.5% BMI reduction versus 2.4% placebo. At 52 weeks, 80% responders achieved 5% BMI reduction. Commercial prep: Sales force expanded from 16 to 42 reps in field since October 2025. Addressable market with 25,000 to 28,000 patients globally. Company has identified 2,000+ suspected diagnosed AHO patients in tier 1-2 practices.
Monday. GSK, Alpha Sigma. Linerat PDUFA, March 24th. Indication: Cholestatic pruritus in primary biliary colitis (PBC). Phase 3 Glisten met primary and key secondary endpoints. Rapid sustained improvement in itch and sleep interference. Deal structure: GSK receives 300M upfront plus 10% FDA approval. Alpha Sigma controls post-approval commercialization. Orphan drug designation US, EU, Japan.
Wednesday. Novo Nordisk AGM, March 26th. Next location: Bella Center, Copenhagen. Key context: Novo Holdings assets declined 34% ($160B -> $107B). NVO down Boston 24% YTD, weaker than expected 2026 guidance citing pricing pressure and competition. Board elections. All shareholder-elected members up for reelection. Three new nominees proposed.
Friday. Rocket Pharma. Chrysladi PDUFA, March 28th. Indication: Severe Leukocyte Adhesion Deficiency Type 1 (LADI). Mechanism: Lentiviral gene therapy delivering functional ITGB2 gene. Phase 1/2 data: 100% overall survival at 12 months and through entire follow-up. All primary/secondary endpoints met. No treatment-related SAEs. Prior CRL June 2024 CMC related. Company aligned with FDA on limited additional information. PRV eligible. If approved, Rocket receives Rare Pediatric Disease Priority Review Voucher.
Read full analysis.
Biomed Nexus Pro.
Institutional Intelligence Briefing.
Today's Pro Brief.
Institutional read-through: Why Ro's hybrid cloud claim and Lily's wholly-owned claim both matter, and why neither proves anything yet. ACIP risk framing scenario analysis for Wednesday's meeting. What a vote on methodology changes could mean for vaccine reimbursement. Rhythm positioning: Pre-PDUFA option flows and what the setup suggests about street expectations. Linerat deal anatomy: Why GSK is exiting hepatology (except HBV, MASH, ALD) and what Alpha Sigma's Intercept acquisition signals about PBC market structure.
Upgrade to Pro today.
Read full article.
Selective 2026 sponsorship placements are available. Reply directly to discuss a partnership or submit an inquiry.